Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P755: HYPERFERRITINEMIA IS A P...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P755: HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML

P755: HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML

Bibliographic Details
Main Authors: L. E. Aguirre, S. Ball, A. Jain, N. Al Ali, D. Sallman, A. Kuykendall, K. Sweet, J. Lancet, E. Padron, R. Komrokji
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000845904.69112.ee
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000845904.69112.ee

Similar Items

  • P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS
    by: Luis E. Aguirre, et al.
    Published: (2023-08-01)
  • <i>IDH</i> mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
    by: Rami Komrokji, et al.
    Published: (2022-11-01)
  • Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
    by: Peter Valent, et al.
    Published: (2019-10-01)
  • Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia
    by: Somedeb Ball, et al.
    Published: (2024-11-01)
  • Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
    by: Rami S. Komrokji, et al.
    Published: (2022-11-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs